Crosstalk between ROR1 and the pre-B-Cell Receptor Promotes Survival of t(1;19) Acute Lymphoblastic Leukemia

por Bicocca, Vincent T., Chang, Bill H., Masouleh, Behzad Kharabi, Muschen, Markus, Loriaux, Marc M., Druker, Brian J., Tyner, Jeffrey W.
Publicado 2012

HitWalker: variant prioritization for personalized functional cancer genomics

por Bottomly, Daniel, Wilmot, Beth, Tyner, Jeffrey W., Eide, Christopher A., Loriaux, Marc M., Druker, Brian J., McWeeney, Shannon K.
Publicado 2013

Comparison of methods to identify aberrant expression patterns in individual patients: augmenting our toolkit for precision medicine

por Bottomly, Daniel, Ryabinin, Peter A, Tyner, Jeffrey W, Chang, Bill H, Loriaux, Marc M, Druker, Brian J, McWeeney, Shannon K, Wilmot, Beth
Publicado 2013

Small molecule inhibitor screen identifies synergistic activity of the bromodomain inhibitor CPI203 and bortezomib in drug resistant myeloma

por Siegel, Matthew B., Liu, Selina Qiuying, Davare, Monika A., Spurgeon, Stephen E., Loriaux, Marc M., Druker, Brian J., Scott, Emma C., Tyner, Jeffrey W.
Publicado en Oncotarget (2015)

CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms

por Tyner, Jeffrey W., Bumm, Thomas G., Deininger, Jutta, Wood, Lisa, Aichberger, Karl J., Loriaux, Marc M., Druker, Brian J., Burns, Christopher J., Fantino, Emmanuelle, Deininger, Michael W.
Publicado 2010

SYK inhibition thwarts the BAFF - B-cell receptor crosstalk and thereby antagonizes Mcl-1 in chronic lymphocytic leukemia

por Paiva, Cody, Rowland, Taylor A., Sreekantham, Bhargava, Godbersen, Claire, Best, Scott R., Kaur, Prabhjot, Loriaux, Marc M., Spurgeon, Stephen E.F., Danilova, Olga V., Danilov, Alexey V.
Publicado en Haematologica (2017)

A potential therapeutic strategy for chronic lymphocytic leukemia by combining Idelalisib and GS-9973, a novel spleen tyrosine kinase (Syk) inhibitor

por Burke, Russell T, Meadows, Sarah, Loriaux, Marc M, Currie, Kevin S., Mitchell, Scott A., Maciejewski, Patricia, Clarke, Astrid S., Dipaolo, Julie A., Druker, Brian J., Lannutti, Brian J., Spurgeon, Stephen E.
Publicado 2014

The CSF3R T618I mutation causes a lethal neutrophilic neoplasia in mice that is responsive to therapeutic JAK inhibition

por Fleischman, Angela G., Maxson, Julia E., Luty, Samuel B., Agarwal, Anupriya, Royer, Lacey R., Abel, Melissa L., MacManiman, Jason D., Loriaux, Marc M., Druker, Brian J., Tyner, Jeffrey W.
Publicado 2013

RNAi screen for rapid therapeutic target identification in leukemia patients

por Tyner, Jeffrey W., Deininger, Michael W., Loriaux, Marc M., Chang, Bill H., Gotlib, Jason R., Willis, Stephanie G., Erickson, Heidi, Kovacsovics, Tibor, O'Hare, Thomas, Heinrich, Michael C., Druker, Brian J.
Publicado 2009

High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients

por Tyner, Jeffrey W., Erickson, Heidi, Deininger, Michael W. N., Willis, Stephanie G., Eide, Christopher A., Levine, Ross L., Heinrich, Michael C., Gattermann, Norbert, Gilliland, D. Gary, Druker, Brian J., Loriaux, Marc M.
Publicado 2009

Met receptor sequence variants R970C and T992I lack transforming capacity

por Tyner, Jeffrey W., Fletcher, Luke B., Wang, Ellen Q., Yang, Wayne F., Rutenberg-Schoenberg, Michael L., Beadling, Carol, Mori, Motomi, Heinrich, Michael C., Deininger, Michael W., Druker, Brian J., Loriaux, Marc M.
Publicado 2010

Potent Activity of Ponatinib (AP24534) in Models of FLT3-Driven Acute Myeloid Leukemia and Other Hematologic Malignancies

por Gozgit, Joseph M., Wong, Matthew J., Wardwell, Scott, Tyner, Jeffrey W., Loriaux, Marc M., Mohemmad, Qurish K., Narasimhan, Narayana I., Shakespeare, William C., Wang, Frank, Druker, Brian J., Clackson, Tim, Rivera, Victor M.
Publicado 2011

The Selective Syk Inhibitor P505-15 (PRT062607) Inhibits B Cell Signaling and Function In Vitro and In Vivo and Augments the Activity of Fludarabine in Chronic Lymphocytic Leukemia

por Spurgeon, Stephen E., Coffey, Greg, Fletcher, Luke B., Burke, Russell, Tyner, Jeffrey W., Druker, Brian J., Betz, Andreas, DeGuzman, Francis, Pak, Yvonne, Baker, Dale, Pandey, Anjali, Hollenbach, Stanley J., Sinha, Uma, Loriaux, Marc M.
Publicado 2013

Therapeutically targetable ALK mutations in leukemia

por Maxson, Julia E., Davare, Monika A., Luty, Samuel B., Eide, Christopher A., Chang, Bill H., Loriaux, Marc M., Tognon, Cristina E., Bottomly, Daniel, Wilmot, Beth, McWeeney, Shannon K., Druker, Brian J., Tyner, Jeffrey W.
Publicado en Cancer Res (2015)

The Colony Stimulating Factor 3 Receptor T640N mutation is oncogenic, sensitive to JAK inhibition, and mimics T618I

por Maxson, Julia E., Luty, Samuel B., MacManiman, Jason D., Paik, Jason C., Gotlib, Jason, Greenberg, Peter, Bahamadi, Swaleh, Savage, Samantha L., Abel, Melissa L., Eide, Christopher A., Loriaux, Marc M., Stevens, Emily A., Tyner, Jeffrey W.
Publicado en Clin Cancer Res (2015)

An Adaptive Src-PDGFRA-Raf Axis in Rhabdomyosarcoma

por Abraham, Jinu, Chua, Ying Xuan, Glover, Jason M., Tyner, Jeffrey W., Loriaux, Marc M., Kilcoyne, Aoife, Giles, Francis J., Nelon, Laura D., Carew, Jennifer S., Ouyang, Yongjian, Michalek, Joel E., Pal, Ranadip, Druker, Brian J., Rubin, Brian P., Keller, Charles
Publicado 2012

CAL-101, a p110δ selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability

por Lannutti, Brian J., Meadows, Sarah A., Herman, Sarah E. M., Kashishian, Adam, Steiner, Bart, Johnson, Amy J., Byrd, John C., Tyner, Jeffrey W., Loriaux, Marc M., Deininger, Mike, Druker, Brian J., Puri, Kamal D., Ulrich, Roger G., Giese, Neill A.
Publicado 2011

Disruption of IKAROS activity in primitive chronic-phase CML cells mimics myeloid disease progression

por Beer, Philip A., Knapp, David J. H. F., Miller, Paul H., Kannan, Nagarajan, Sloma, Ivan, Heel, Kathy, Babovic, Sonja, Bulaeva, Elizabeth, Rabu, Gabrielle, Terry, Jefferson, Druker, Brian J., Loriaux, Marc M., Loeb, Keith R., Radich, Jerald P., Erber, Wendy N., Eaves, Connie J.
Publicado en Blood (2015)

Targeting of colony-stimulating factor 1 receptor (CSF1R) in the CLL microenvironment yields antineoplastic activity in primary patient samples

por Edwards V, David K., Sweeney, David Tyler, Ho, Hibery, Eide, Christopher A., Rofelty, Angela, Agarwal, Anupriya, Liu, Selina Qiuying, Danilov, Alexey V., Lee, Patrice, Chantry, David, McWeeney, Shannon K., Druker, Brian J., Tyner, Jeffrey W., Spurgeon, Stephen E., Loriaux, Marc M.
Publicado en Oncotarget (2018)

TSLP Signaling Network Revealed by SILAC-Based Phosphoproteomics

por Zhong, Jun, Kim, Min-Sik, Chaerkady, Raghothama, Wu, Xinyan, Huang, Tai-Chung, Getnet, Derese, Mitchell, Christopher J., Palapetta, Shyam M., Sharma, Jyoti, O'Meally, Robert N., Cole, Robert N., Yoda, Akinori, Moritz, Albrecht, Loriaux, Marc M., Rush, John, Weinstock, David M., Tyner, Jeffrey W., Pandey, Akhilesh
Publicado 2012